InVivo Therapeutics appoints Christopher McNulty as CFO
Prior to being appointed Chief Financial Officer, Mr. McNulty served at InVivo as Senior Vice President, Business Development and Investor Relations, where he was responsible for evaluating all partnerships and licensing opportunities.
In addition to his responsibilities in business development, Mr. McNulty played a key role in the company’s financings, including a follow-on offering and registered direct financing.
Prior to joining InVivo, Mr. McNulty served as Senior Director, Business Development of Repligen Corporation.
At Repligen, he led all aspects of the company’s acquisition of Novozymes Sweden, including financial modeling, diligence, strategy, and negotiation.
Previously, Mr. McNulty served as Director, Corporate Development at Seventh Sense Biosystems, where he was responsible for corporate strategy, market evaluation, and business development.
Mr. McNulty received his B.S. and M.Eng. degrees in electrical engineering and computer science from MIT, and his M.B.A. from Harvard Business School. ■
What to read next
LATEST MOVES FROM Massachusetts
- RXI Pharma names Gerrit Dispersyn chief development officer
- resTORbio appoints Joan Mannick as CMO
- C&W Services appoints Mike Losier as director
- Charles River Associates appoints Robert A. Whitman to board
- Ironwood Pharmaceuticals appoints Christopher Wright as SVP
More inside POST